Next Article in Journal
Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies
Previous Article in Journal
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Previous Article in Special Issue
The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting
Open AccessReview

Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer

by 1,†, 2,†, 3,4, 2, 5,6,* and 2,7,8,9,*
1
Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan
2
Department of Life Sciences, National Taiwan University, Taipei 10617, Taiwan
3
Department of Biotechnology, Asia University, Taichung 41354, Taiwan
4
Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan
5
Department of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan
6
Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan
7
Department of Electrical Engineering, National Taiwan University, Taipei 10617, Taiwan
8
Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei 10617, Taiwan
9
Center for Biotechnology, National Taiwan University, Taipei 10617, Taiwan
*
Authors to whom correspondence should be addressed.
First authors.
Cancers 2018, 10(11), 413; https://doi.org/10.3390/cancers10110413
Received: 7 October 2018 / Revised: 28 October 2018 / Accepted: 29 October 2018 / Published: 31 October 2018
(This article belongs to the Special Issue Tumor Angiogenesis: An Update)
Prostate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalities for advanced PCa is crucial. Many tumors, including PCa, first metastasize to regional lymph nodes via lymphatic vessels. Recent findings demonstrate that the bioactive lipid lysophosphatidic acid (LPA) promotes PCa progression by regulating vascular endothelial growth factor-C (VEGF-C), a critical mediator of tumor lymphangiogenesis and lymphatic metastasis. Many of the underlying molecular mechanisms of the LPA–VEGF-C axis have been described, revealing potential biomarkers and therapeutic targets that may aid in the diagnosis and treatment of advanced PCa. Herein, we review the literature that illustrates a functional role for LPA signaling in PCa progression. These discoveries may be especially applicable to anti-lymphangiogenic strategies for the prevention and therapy of metastatic PCa. View Full-Text
Keywords: LPA; LPA receptor; prostate cancer; VEGF-C; lymphangiogenesis LPA; LPA receptor; prostate cancer; VEGF-C; lymphangiogenesis
Show Figures

Figure 1

MDPI and ACS Style

Wu, P.-Y.; Lin, Y.-C.; Huang, Y.-L.; Chen, W.-M.; Chen, C.-C.; Lee, H. Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer. Cancers 2018, 10, 413.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop